论文部分内容阅读
主动脉瓣狭窄和动脉粥样硬化性疾病有很多共同的危险因素,尤其是高胆固醇血症。在组织学上,病变的瓣膜似乎具有与动脉粥样硬化斑块非常相似的炎症区域。降脂治疗对主动脉瓣狭窄(AS)进展的影响尚不清楚,而且尚没有相关的随机治疗试验评价这类患者中的心血管发病率和死亡率。SEAS(辛伐他汀和依泽替米贝应用于主动脉瓣狭窄)是一项随机、双盲、安慰剂对照的多中心研究,旨在在至少4年的研究期内观察辛伐他汀40m g/d或依泽替米贝10m g/d的降脂治疗对跨瓣射血峰值速度为2.5～4.0m/s的无症状AS患者的作用。主要的疗效指标为主动脉瓣手术和缺血性血管事件,包括心血管疾病死亡;次要终点为利用超声心动图观察的对AS进展的影响。
There are many common risk factors for aortic stenosis and atherosclerotic disease, especially hypercholesterolemia. Histologically, diseased valves appear to have areas of inflammation that are very similar to atherosclerotic plaques. The effect of lipid-lowering therapy on the progression of aortic stenosis (AS) is unclear and no relevant randomized trial has evaluated cardiovascular morbidity and mortality in these patients. SEAS (Simvastatin and Ezetimibe for aortic stenosis) is a randomized, double-blind, placebo-controlled, multicenter study designed to observe the effects of simvastatin 40 m g over a study period of at least 4 years / d or ezetimibe 10m g / d lipid-lowering treatment on the role of asymptomatic AS patients with a cross-valve ejection peak velocity of 2.5 ~ 4.0m / s. The primary outcome measures were aortic valve surgery and ischemic vascular events, including death from cardiovascular disease; the secondary endpoint was the effect of echocardiography on AS progression.